S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:YMTX

Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

$0.52
-0.03 (-5.44%)
(As of 03/27/2024 ET)
Today's Range
$0.51
$0.60
50-Day Range
$0.52
$2.83
52-Week Range
$0.95
$13.23
Volume
99,011 shs
Average Volume
473,083 shs
Market Capitalization
$5.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
YMTX stock logo

About Yumanity Therapeutics Stock (NASDAQ:YMTX)

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

YMTX Stock Price History

YMTX Stock News Headlines

JSPR Jasper Therapeutics, Inc.
Cara Therapeutics Inc CARA
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Yumanity Therapeutics Inc.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Why Is Yumanity Therapeutics (YMTX) Stock Up Today?
See More Headlines
Receive YMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yumanity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:YMTX
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

Net Income
$-39,500,000.00
Net Margins
-660.61%
Pretax Margin
-660.61%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Book Value
$2.28 per share

Miscellaneous

Free Float
9,504,000
Market Cap
$5.66 million
Optionable
Not Optionable
Beta
0.32
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Richard Peters M.D. (Age 59)
    Ph.D., CEO, Pres & Director
    Comp: $896.1k
  • Dr. Vikram Khurana M.D.
    Ph.D., Scientific Co-Founder & Sr. Advisor of Discovery Biology
  • Ms. Chee Yeun Chung Ph.D.
    Scientific Co-Founder & Associate Director of Discovery Biology
  • Ms. Marie Epstein CPA
    VP of Fin.
  • Mr. Michael D. Wyzga (Age 33)
    SVP, CFO & Treasurer
  • Mr. Devin Whittemore Smith (Age 54)
    SVP, Gen. Counsel & Sec.

YMTX Stock Analysis - Frequently Asked Questions

How have YMTX shares performed in 2024?

Yumanity Therapeutics' stock was trading at $3.63 at the start of the year. Since then, YMTX stock has decreased by 85.6% and is now trading at $0.5213.
View the best growth stocks for 2024 here
.

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) released its quarterly earnings results on Thursday, August, 12th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.19. The firm earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

How do I buy shares of Yumanity Therapeutics?

Shares of YMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:YMTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners